Löfdahl C-G, Postma D S, Pride N B, Boe J, Thorén A
Department of Respiratory Medicine and Allergology, University Hospital, SE-22185 Lund, Sweden.
Eur Respir J. 2007 Jun;29(6):1115-9. doi: 10.1183/09031936.00128806. Epub 2007 Mar 1.
Epidemiological studies have indicated that chronic obstructive pulmonary disease (COPD) may be associated with an increased incidence of ischaemic cardiac events. The current authors performed a post hoc analysis of the European Respiratory Society's study on Chronic Obstructive Pulmonary Disease (EUROSCOP); a 3-yr, placebo-controlled study of an inhaled corticosteroid budesonide 800 microg.day(-1) in smokers (mean age 52 yrs) with mild COPD. The current study evaluates whether long-term budesonide treatment attenuates the incidence of ischaemic cardiac events, including angina pectoris, myocardial infarction, coronary artery disorder and myocardial ischaemia. Among the 1,175 patients evaluated for safety, 49 (4.2%) patients experienced 60 ischaemic cardiac events. Patients treated with budesonide had a significantly lower incidence of ischaemic cardiac events (18 out of 593; 3.0%) than those receiving placebo (31 out of 582; 5.3%). The results of the present study support the hypothesis that treatment with inhaled budesonide reduces ischaemic cardiac events in patients with mild chronic obstructive pulmonary disease.
流行病学研究表明，慢性阻塞性肺疾病（COPD）可能与缺血性心脏事件的发病率增加有关。本文作者对欧洲呼吸学会关于慢性阻塞性肺疾病的研究（EUROSCOP）进行了一项事后分析；这是一项为期3年的、针对轻度COPD吸烟者（平均年龄52岁）吸入布地奈德800微克/天的安慰剂对照研究。本研究评估长期布地奈德治疗是否能降低缺血性心脏事件的发生率，包括心绞痛、心肌梗死、冠状动脉疾病和心肌缺血。在1175例接受安全性评估的患者中，49例（4.2%）患者发生了60次缺血性心脏事件。接受布地奈德治疗的患者缺血性心脏事件的发生率（593例中有18例；3.0%）显著低于接受安慰剂治疗的患者（582例中有31例；5.3%）。本研究结果支持以下假设：吸入布地奈德治疗可降低轻度慢性阻塞性肺疾病患者的缺血性心脏事件发生率。
